ASCENTAGE PHARMA GROUP INTERNATIONAL
AAPG · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $980,650 | $221,984 | $209,711 | $27,910 |
| % Growth | 341.8% | 5.9% | 651.4% | – |
| Cost of Goods Sold | $29,085 | $30,543 | $21,998 | $3,328 |
| Gross Profit | $951,565 | $191,441 | $187,713 | $24,582 |
| % Margin | 97% | 86.2% | 89.5% | 88.1% |
| R&D Expenses | $947,245 | $706,972 | $743,104 | $766,491 |
| G&A Expenses | $187,125 | $181,076 | $170,595 | $143,513 |
| SG&A Expenses | $383,123 | $376,463 | $328,016 | $191,261 |
| Sales & Mktg Exp. | $195,998 | $195,387 | $157,421 | $47,748 |
| Other Operating Expenses | -$9,073 | -$19,358 | -$33,597 | -$63,335 |
| Operating Expenses | $1,321,295 | $1,064,077 | $1,037,523 | $894,417 |
| Operating Income | -$369,730 | -$872,636 | -$849,810 | -$869,835 |
| % Margin | -37.7% | -393.1% | -405.2% | -3,116.6% |
| Other Income/Exp. Net | -$25,525 | -$60,226 | -$37,362 | $37,586 |
| Pre-Tax Income | -$395,255 | -$932,862 | -$887,172 | -$832,249 |
| Tax Expense | $10,425 | -$7,150 | -$4,248 | -$49,825 |
| Net Income | -$405,433 | -$925,637 | -$882,924 | -$782,424 |
| % Margin | -41.3% | -417% | -421% | -2,803.4% |
| EPS | -1.34 | -13.12 | -13.4 | -12.28 |
| % Growth | 89.8% | 2.1% | -9.1% | – |
| EPS Diluted | -1.34 | -13.12 | -13.4 | -12.28 |
| Weighted Avg Shares Out | 302,062 | 70,575 | 65,917 | 63,654 |
| Weighted Avg Shares Out Dil | 302,062 | 70,575 | 65,917 | 63,654 |
| Supplemental Information | – | – | – | – |
| Interest Income | $37,840 | $32,409 | $9,727 | $7,106 |
| Interest Expense | $64,455 | $96,057 | $52,785 | $16,731 |
| Depreciation & Amortization | $93,169 | $93,195 | $47,421 | $17,183 |
| EBITDA | -$237,631 | -$743,610 | -$786,966 | -$798,335 |
| % Margin | -24.2% | -335% | -375.3% | -2,860.4% |